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Background: This study aims to quantitatively and qualitatively assess microvascular complications and their risk factors in patients with cystic
fibrosis-related diabetes (CFRD) compared to those with type 1 diabetes mellitus (DM1).
Methods: 79 patients with CFRD were matched with 79 patients with DM1 according to sex, age and duration of insulin therapy. Retinopathy,
peripheral neuropathy, nephropathy and microalbuminuria were the microvascular complications assessed. Risk factors studied were: smoking,
BMI, HbA1c, cholesterol, cholesterol/HDL ratio, diastolic and systolic blood pressure.
Results: Both groups had the same number of microvascular complications (29%). CFRD patients showed more microalbuminuria (21% versus
4.1%; p=0.003), while retinopathy was more common in patients with DM1 (24% versus 10%; p=0.044). The prevalences of peripheral
neuropathy and nephropathy were similar. Patients with CFRD had lower BMI (pb0.0001), total cholesterol (pb0.0001) and HbA1c (p=0.056)
levels, and a lower prevalence of smokers (pb0.0001). Cholesterol/HDL ratio and diastolic and systolic blood pressure were similar in both
groups.
Conclusions: The microvascular complications shown by patients with CFRD are similar to those seen in patients with DM1 but with a lower
prevalence of retinopathy and a higher prevalence of microalbuminuria. The latter may reflect the influence of other cystic fibrosis-related factors
on renal function.
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Cystic fibrosis (CF) is the most common life-threatening
autosomal recessive disorder amongCaucasianswith an estimated
prevalence of one per 4750 live births in the Netherlands [1].
Mutations in the CFTR-gene on chromosome 7 result in an
impaired salt transport at the apical membrane of epithelial cells.
This results in alterations in the composition of airway lining fluid⁎ Corresponding author. Tel.: +31 702102076; fax: +31 702102150.
E-mail address: j.m.w.vandenberg@hagaziekenhuis.nl (J.M.W. van den Berg).
1569-1993/$ - see front matter © 2008 European Cystic Fibrosis Society. Publishe
doi:10.1016/j.jcf.2008.05.008and secretions in various organs, e.g. the pancreas and biliary
channels [2]. Current median life expectancy is over 35 years [3].
One of themost frequent co-morbidities seen in adult patients with
CF is cystic fibrosis-related diabetes (CFRD), with an overall
prevalence of 12%, and increasing with age; ∼up to 50% for
patients over 30 years [3].
CFRD is caused by relative insulin deficiency and insulin
resistance. Although it shows similarities to both type 1 and
type 2 diabetes mellitus, it is a clinically separate entity. The
primary component, insulin deficiency, results from disturbed
pancreatic function as a consequence of the destruction of
pancreatic tissue, diminished pancreatic blood flow and chronicd by Elsevier B.V. All rights reserved.
Table 1
Demographic characteristics of the two patient groups
Characteristics No. of pairs CFRDa DM I b P value
Sex – no. (%) 79
Male 38(48) 38(48)
Female 41(52) 41(52)
Age – yr 79
Mean 31.1 30.8 0.844
Range 17.3–63.1 17.0–62.2
Duration of insulin therapy – yr 79
Mean 6.63 6.90 0.672
Range 0–21 0–21
a CFRD=cystic fibrosis-related diabetes.
b DM I=type 1 diabetes mellitus.
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CF, is exacerbated by respiratory infections and corticosteroid
treatment, and may fluctuate over time [4,5].
Previously, life expectancy for patients with CF and CFRD
was considered to be too short for the development of diabetic
complications, but greater longevity has now been accompanied
by increasing reports of microvascular complications [6–12],
though macroangiopathy as complication of CFRD has never
been proven. Two recent studies described the presence of
microvascular complications in their patient populations
including post-transplantation patients [13,14]. They reported
a prevalence of retinopathy in respectively 27% and 16%,
predominantly seen in patients with a duration of the diabetes of
at least 10 years. Microalbuminuria was reported in respectively
13% and 7% of the total patient groups. In a selected subgroup
of CFRD patients described by Schwarzenberg et al., neurologic
complications, i.e. autonomic and peripheral neuropathy, were
seen in respectively 34% and 17% of the patients and
gastrointestinal complications in 51% of these patients [14].
In the study of Andersen et al. peripheral neuropathy was only
seen in 3 transplanted patients [13]. Other complications were
only seen in a small number of patients.
Although the prevalence of late diabetic complications in
CFRD is known, no study has compared the frequency and
severity of microvascular complications between patients with
CFRD and those with type 1 diabetes mellitus. In both these
patient groups insulin deficiency is the main cause of glucose
intolerance. Patients with CFRD may have fewer risk factors for
the development of late diabetic complications, such as
hypertension, high serum cholesterol and smoking. Therefore,
we hypothesize that patients with CFRD may be less prone to
develop late diabetic complications in comparison to patients
with type 1 diabetes mellitus. In this study, risk factors for, and
the prevalence of, microvascular complications were compared
in patients with CFRD and a matched group of patients with
type 1 diabetes mellitus.
2. Methods
2.1. Patients
The study population consisted of 79 patients with CF (38
men) and insulin dependent CFRD from a total of 480 adult
patients with CF (ageN17 yrs) who were attending the adult
cystic fibrosis centres in The Hague, The Netherlands (194),
and Leeds, United Kingdom (286). In accordance with
international guidelines, CFRD was diagnosed using an oral
glucose tolerance test (OGTT) and if inconclusive, in addition a
one-day self-monitoring was performed [15]. Patients were
excluded if they were post lung transplants or pregnant, had
biopsy proven renal disease other than diabetic nephropathy, or
positive islet cell antibodies. Seven eligible patients did not
want to participate in the study.
Seventy-nine patients with type 1 diabetes mellitus attending
the department of endocrinology at Leiden University Medical
Center and matched for age, gender and duration of insulin
therapy formed the control group. Informed consent was givenby all patients. The demographic characteristics of both groups
are shown in Table 1.
2.2. Study design
Blood and urine samples were collected from patients at
routine outpatient visits. All patients were free from pulmonary
exacerbations and were not on intravenous antibiotic therapy.
The samples were analysed for total cholesterol and glycated
haemoglobin (HbA1c), and microalbuminuria respectively.
Body Mass Index (BMI, weight (kg) /height (m)2) and the
mean of two blood pressure measurements on the right arm
were noted. Renal damage was assessed by the albumin/
creatinine ratio, in grams of albumin per mol creatinine.
Microalbuminuria was defined as ratios of 2.5–25 for men and
3.5–35 for women. Ratios exceeding this range were defined as
macroalbuminuria and diabetic nephropathy [16]. Peripheral
neuropathy was assessed as present or absent by monofilament
testing on the feet (Semmes Weinstein monofilament,
5.07=10 g). Positive results were confirmed by examination
according to international guidelines of the European Associa-
tion for the Study of Diabetes [17,18]. Diabetic autonomic
neuropathy was not assessed, as the physical condition of most
CFRD patients does not allow them to undergo this test (heart-
rate response to deep breathing). All patients were assessed by
the ophthalmologist at their cystic fibrosis centre using
opthalmoscopy, which was common practice in all clinics. As
staging of retinopathy was different between the clinics,
retinopathy was scored as present or absent.
The data of patients with type 1 diabetes mellitus were
collected from their annual hospital review.
2.3. Analytical methods
In all three centres that participated in this study, laboratory
tests were standardized using local protocols. HbA1c was
measured in all clinics with an HPLC system (Variant, Biorad).
Total cholesterol and HDL cholesterol were measured on a fully
automated P-800 from Roche, a Syncron LX20 from Beckmann
Couller or an ADVIA 2400 analyzer from Bayer in the hospitals
of Leiden, The Hague and Leeds, respectively. Urine analysis
Table 3
Frequency of late diabetic complications
Late complications No. of pairs CFRDa DM I b P value
Retinopathy – no. (%) 70 7 (10) 17 (24.3) 0.044
Neuropathy – no. (%) 70 2 (2.9) 3 (4.3) 0.649
Nephropathy – no. (%) 62 1 (1.6) 1 (1.6) 0.900
Microalbuminuria c – no. (%) 62 13 (21.0) 2 (3.2) 0.002
a CFRD=cystic fibrosis-related diabetes.
b DM I=type 1 diabetes mellitus.
c Microalbuminuria: men 2.5–25 g/mol creatinine: women 3.5–35 g/mol
creatinine.
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from Beckmann Couller or an ADVIA 1650 from Bayer,
respectively.
2.4. Statistical analysis
All patients with CFRD were matched with a non-CF type 1
diabetes mellitus patient (Table 1). They were matched according
to sex, age (with amaximumdiscrepancy of one year) and duration
of insulin therapy (with a maximum discrepancy of one year).
In the statistical analysis, continuous variables were compared
by a non-parametric Wilcoxon–Mann–Whitney test. Categorical
variables were compared by Chi-Square testing. Probabilities of
less than 0.05 were considered significant. All p-values were two-
tailed. Data were analysed with SPSS 11.0 statistical package
(SPSS Inc., Chicago, IL, USA).
3. Results
3.1. Risk factors
Differences in risk factors for late diabetic complications for
both groups of patients are shown in Table 2. The CFRD group
had lower BMI (pb0.0001) and total cholesterol (pb0.0001),
and less smokers (pb0.0001). The cholesterol/HDL cholesterol
ratio was not statistically different between the two groups.
Patients with CFRD tended to have a lower HbA1C, but the
difference was not significant (p=0.056). Neither systolic nor
diastolic blood pressure measurements differed significantly
between the two groups, although a trend could be distinguished
towards a lower diastolic blood pressure among patients with
CFRD (p=0.062).Table 2
Prevalence of risk factors for microvascular complications of diabetes
Risk factors No. of
pairs
CFRDa DM I b P value
Smoking (%) 61 0 (0) 24 (32) b0.0001
BMI 75
Median 21.0 22.0 b0.0001
Range 14.3–28.5 16.1–38.3
HbA1c – % 79
Median 6.8 7.4 0.056
Range 5.4–9.5 3–13.4
Total cholesterol – mmol/l 76
Median 3.6 4.6 b0.0001
Range 1.9–6.1 3.0–7.7
Cholesterol/HDL ratio 72
Median 3.21 3.04 0.345
Range 1.86–6.17 1.70–8.39
Systolic blood pressure – mmHg 79
Median 120 125 0.308
Range 94–148 100–191
Diastolic blood pressure – mmHg 79
Median 72 75 0.062
Range 46–110 55–110
a CFRD=cystic fibrosis-related diabetes.
b DM I=type 1 diabetes mellitus.3.2. Microvascular complications
In both the CFRD and type 1 diabetes mellitus groups, 19
patients had 23 microvascular complications (Table 3). Two
patients with CFRD had both microalbuminuria and retinopathy
and one patient had retinopathy, peripheral neuropathy and
nephropathy. Two patients with type 1 diabetes mellitus had
both retinopathy and neuropathy, one patient had retinopathy
and microalbuminuria, and one patient had retinopathy and
nephropathy. There was no statistical difference in the
prevalence of peripheral neuropathy (p=0.900) or nephropathy
(p=0.649) between the two groups. Retinopathy occurred
significantly more frequent in the group with type 1 diabetes
mellitus (p=0.044). Microalbuminuria was more common
(p=0.002), and the median albumin/creatinine ratio higher
(pb0.0001), in the CFRD patient group (Fig. 1). Two patients
with nephropathy in both groups were excluded from this
analysis, as their level of proteinuria exceeded the upper limit of
definition for microalbuminuria. Presence of late diabeticFig. 1. Microalbuminuria in g/mol creat for CFRD and type 1 diabetes mellitus
(logarithmic scale). – – – – = limit microalbuminuria 3.5 g/mol creatinine in
women. - - - - - - = limit microalbuminuria 2.5 g/mol creatinine in men.
Microalbuminuria in g/mol creat: median for CFRD is 1.0 (range 0.2–21.6) and
for DM I 0.4 (range 0.1–5.6) (pb0.0001).
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due to incomplete clinical data (Table 3).
4. Discussion
This is the first study comparing microvascular complica-
tions in CFRD with type 1 diabetes mellitus in matched pairs.
Patients with CFRD showed a higher prevalence of micro-
albuminuria and a lower prevalence of retinopathy. There were
no statistical differences between the groups in the prevalence
of nephropathy and peripheral neuropathy.
The greater prevalence of retinopathy in the type 1 diabetes
mellitus group may reflect the fact that smoking, high
cholesterol levels, and high BMI were significantly more
common in these patients. The tendencies of a better diabetic
regulation expressed as HbA1c and a lower blood pressure in
patients with CFRD may contribute to this in the same way. It is
generally thought that chronic hyperglycaemia is the main cause
of diabetic retinopathy [19]. HbA1c reflects mean glycaemic
levels over a longer period of time and one study has
demonstrated this is also reliable in cystic fibrosis patients
[20]. The higher prevalence of retinopathy in type 1 diabetic
patients can therefore probably be best explained by the
tendency towards higher HbA1c levels in this patient group.
The discrepancy between the retinopathy and microalbumi-
nuria in patients with CFRD suggests that other factors might
contribute to the renal microangiopathy found in this group, e.g.
a deficiency of renal cystic fibrosis transmembrane regulator
protein function, a genetic predisposition, exercise proteinuria,
insulin resistance [21], chronic inflammation [22–24], or
repeated treatment with potentially nephrotoxic drugs, such as
corticosteroids and aminoglycoside antibiotics [25]. Although
aminoglycosides are potentially nephrotoxic, it is unlikely that
the microalbuminuria found in this patient population can be
ascribed to the use of these drugs. It has been reported that
aminoglycoside nephrotoxicity primarily manifests in acute
tubular necrosis (ATN) [25]. Proteinuria during aminoglycoside
use has been described as well, but this mainly comprises low
molecular weight protein, suggesting presence of tubular
proteinuria instead of glomerular proteinuria with macromole-
cules such as albumin [26]. Moreover, proteinuria occurring
during aminoglycoside use is reported to return to preexisting
levels after cessation of therapy [27]. In our study none of the
patients were on intravenous antibiotic therapy during the study.
Besides, we tried to avoid potential bias with regard to inflam-
mation by collecting blood and urine samples during exacer-
bation-free periods. Other renal or systemic disorders, such as
IgA nephropathy, amyloidosis, ANCA-associated glomerulone-
phritis and tubulointerstitial nephritis are also more common in
patients with CF and might be yet undiagnosed [28–31].
Although patients with CFRD had a lower BMI, plasma
creatinine levels and excretion were within the normal range,
which therefore could not explain a falsely higher value of the
albumin/creatinine ratio. Furthermore, a recent study showed a
higher prevalence of microalbuminuria in patients with CF
without diabetes in comparison to healthy controls (mean ratio
1.2 versus 0.5 g/mol creat) [32]. This may indicate a potentialshare of until now unknown CF-related factors other than
CFRD, in the onset of microalbuminuria.
Until recently, microvascular complications in CFRD have
only been reported in case studies or in small numbers of
patients. In the past year, two studies were published, describing
the presence of microvascular complications in patients with
CFRD [13,14]. The first study reported retinopathy in 25% and
microalbuminuria in 13% of their non-transplanted CFRD
patients, in comparison with a prevalence of 10% and 21% in
this study, respectively. In the second study different patient
groups and inclusion criteria were used, therefore it cannot be
properly compared to this study. Although both these studies
give an insight in the prevalence of microvascular complica-
tions in CFRD, this study is the first to describe the prevalence
of microvascular complications in a large homogenous group of
patients with CFRD, and compared these results with the
prevalence of microvascular complications in matched patients
with type 1 diabetes mellitus.
Despite the limited number of patients with CFRD, this
international collaboration study identified a sufficient number of
patients to analyze the prevalence of microvascular complication.
However, the group was not large enough to performmultivariate
analysis with statistically relevant outcome. At last it is important
to recognize potential bias due to interlaboratory differences. It is
however unlikely that this fully explains the great differences
between both patient groups in our study.
In conclusion, this study has shown that overall the prevalence
of microvascular complications in patients with CFRD is similar
to that in patients with type 1 diabetes mellitus. Retinopathy was
less, andmicroalbuminuriamore common in patientswith CFRD.
The latter discrepancy may be due to the additive nephrotoxic
effect of other CF-related factors.
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